Table 2.

Mouse xenograft result summary

TreatmentScheduleTGI (%)Tumor regressionTumor necrosisDeaths
H460 cell xenografts
 ControlQD×5000
 PTX 8 mg/kgQD×553%b000
 DTX 6.3 mg/kgQ2D×319%000
 PLA 5 mg/kgQD×588%b000
 PLA 10 mg/kgQD×599%b53% (1)00
 PLA 20 mg/kgQD×57 (d8)
 PLA and DTXAs above99%c001 (d8), 1 (d12)
 PLA and PTXAs above7 (d8)
A549 cell xenografts
 ControlQD×50mod (2), sev (2)0
 PTX 16 mg/kgQD×544%a0mild (2), mod (2), sev (2)0
 DTX 13 mg/kgQ2D×350%a0mild (1), mod (3), sev (2)0
 PLA 5 mg/kgQD×574%b0mild (1), mod (1)0
 PLA 10 mg/kgQD×571%b000
 PLA 10 mg/kgQ2D×351%b0mild (3), mod (1), sev (1)0
 PLA 15 mg/kgQ2D×370%b0mild (2), mod (3)0
ADR-RES cell xenografts
 ControlQD×5(1)mild (1), mod (1), sev (4)0
 PTX 16 mg/kgQD × 5 × 286%b20% (1), 100% (1)sev (1)2 (d11), 1 (d26)
 DOXO 2.5 mg/kgQD × 567%a100% (1)mod (1), sev (1)1 (d22), 1 (d26), 1 (d36)
 PLA 5 mg/kgQD × 5 × 368%b100% (1)sev (5)0
 PLA 10 mg/kgQD × 519%0sev (6)0
 PLA 15 mg/kgQ2D × 356%a100% (1)mod (1), sev (3)0
 PLA 15 mg/kgQ2D × 4 × 373%b100% (1)mod (1), sev (4)1 (d26)

NOTE: Cancer cell xenografts in nu/nu mice were treated with peloruside A (PLA), docetaxel (DTX), paclitaxel (PTX), or doxorubicin (DOXO). There were 7 animals per group, and the number of animals in each group that showed tumor regression or tumor necrosis [mild, moderate (mod), or severe (sev)] are indicated in parentheses. In the combination experiments with H460 cells, animals were treated with PLA (i.p. 5 mg/kg) and either DTX (i.v. 6.3 mg/kg) or PTX (i.p. 8 mg/kg).

  • aP < 0.05.

  • bP < 0.01.

  • cP < 0.0001, one-way ANOVA with the Dunnett post hoc test.